SP9

Summary

SP9 (Sp9 transcription factor, HGNC:30690) is a protein-coding gene on chromosome 2q31.1, encoding Transcription factor Sp9 (P0CG40). Transcription factor which plays a key role in limb development.

Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in chromatin.

Source: NCBI Gene 100131390 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 58 total — 4 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001145250

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30690
Approved symbol	SP9
Name	Sp9 transcription factor
Location	2q31.1
Locus type	gene with protein product
Status	Approved
Aliases	ZNF990
Ensembl gene	ENSG00000217236
Ensembl biotype	protein_coding
OMIM	621003
Entrez	100131390

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000394967

RefSeq mRNA: 1 — MANE Select: NM_001145250 NM_001145250

CCDS: CCDS46453

Canonical transcript exons

ENST00000394967 — 2 exons

Exon	Start	End
ENSE00001559933	174334954	174335113
ENSE00001560331	174336107	174338500

Expression profiles

Bgee: expression breadth broad, 44 present calls, max score 88.52.

FANTOM5 (CAGE): breadth broad, TPM avg 0.8502 / max 96.9834, expressed in 197 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
23790	0.6013	147
23791	0.2489	104

Top tissues by expression

125 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.82	gold quality
ganglionic eminence	UBERON:0004023	69.89	gold quality
putamen	UBERON:0001874	68.38	gold quality
prefrontal cortex	UBERON:0000451	68.19	gold quality
nucleus accumbens	UBERON:0001882	68.08	gold quality
caudate nucleus	UBERON:0001873	67.70	gold quality
anterior cingulate cortex	UBERON:0009835	67.44	gold quality
superior frontal gyrus	UBERON:0002661	65.60	gold quality
Brodmann (1909) area 9	UBERON:0013540	64.47	gold quality
frontal cortex	UBERON:0001870	64.42	gold quality
ventricular zone	UBERON:0003053	64.41	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	64.38	gold quality
temporal lobe	UBERON:0001871	64.37	gold quality
amygdala	UBERON:0001876	64.22	gold quality
stromal cell of endometrium	CL:0002255	64.17	gold quality
cerebral cortex	UBERON:0000956	63.54	gold quality
primary visual cortex	UBERON:0002436	63.02	gold quality
cortical plate	UBERON:0005343	62.61	gold quality
right frontal lobe	UBERON:0002810	58.74	gold quality
Ammon’s horn	UBERON:0001954	56.49	gold quality
hypothalamus	UBERON:0001898	56.22	gold quality
bone marrow cell	CL:0002092	55.25	gold quality
brain	UBERON:0000955	54.47	gold quality
colonic epithelium	UBERON:0000397	53.32	gold quality
skin of abdomen	UBERON:0001416	51.50	gold quality
substantia nigra	UBERON:0002038	49.48	gold quality
fallopian tube	UBERON:0003889	47.91	gold quality
right uterine tube	UBERON:0001302	47.03	gold quality
placenta	UBERON:0001987	45.21	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	18.99
E-MTAB-8894	no	469.01
E-ANND-3	no	0.33

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA1564.1	SP9	Three-zinc finger Kruppel-related
MA1564.2	SP9	Three-zinc finger Kruppel-related

JASPAR matrix evidence (PMIDs): PMID:26187067

Literature-anchored findings (GeneRIF, showing 1)

• De novo variants in SP9 cause a novel form of interneuronopathy characterized by intellectual disability, autism spectrum disorder, and epilepsy with variable expressivity. (PMID:38288683)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	sp9	ENSDARG00000099374
mus_musculus	Sp9	ENSMUSG00000068859
rattus_norvegicus	Sp9	ENSRNOG00000028187
drosophila_melanogaster	luna	FBGN0040765

Paralogs (22): KLF6 (ENSG00000067082), KLF8 (ENSG00000102349), KLF5 (ENSG00000102554), KLF1 (ENSG00000105610), KLF3 (ENSG00000109787), KLF7 (ENSG00000118263), KLF12 (ENSG00000118922), KLF9 (ENSG00000119138), KLF2 (ENSG00000127528), KLF16 (ENSG00000129911), KLF4 (ENSG00000136826), KLF10 (ENSG00000155090), KLF15 (ENSG00000163884), SP8 (ENSG00000164651), KLF13 (ENSG00000169926), SP7 (ENSG00000170374), KLF17 (ENSG00000171872), KLF11 (ENSG00000172059), SP6 (ENSG00000189120), SP5 (ENSG00000204335), KLF14 (ENSG00000266265), KLF18 (ENSG00000283039)

Protein

Protein identifiers

Transcription factor Sp9 — P0CG40 (reviewed: P0CG40)

All UniProt accessions (1): P0CG40

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor which plays a key role in limb development. Positively regulates FGF8 expression in the apical ectodermal ridge (AER) and contributes to limb outgrowth in embryos.

Subcellular location. Nucleus.

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. In SP9, the motif is inactive.

Similarity. Belongs to the Sp1 C2H2-type zinc-finger protein family.

RefSeq proteins (1): NP_001138722* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (7 total): zinc finger region 3, chain 1, region of interest 1, short sequence motif 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0CG40-F1	49.04	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 440

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 21 (showing top): GOBP_APPENDAGE_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT, MARSON_BOUND_BY_E2F4_UNSTIMULATED, GOBP_EMBRYONIC_MORPHOGENESIS, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, GOBP_APPENDAGE_MORPHOGENESIS, GOBP_EMBRYONIC_APPENDAGE_MORPHOGENESIS, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ZNF146_TARGET_GENES, BLANCO_MELO_INFLUENZA_A_INFECTION_A594_CELLS_DN, BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_CELLS_DN, DESCARTES_MAIN_FETAL_SATB2_LRRC7_POSITIVE_CELLS, GOMF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, GOMF_CIS_REGULATORY_REGION_SEQUENCE_SPECIFIC_DNA_BINDING

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), embryonic limb morphogenesis (GO:0030326)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
limb morphogenesis	1
embryonic appendage morphogenesis	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
DNA binding	1
cation binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SP9	ACRV1	P26436	883
SP9	LIPN	Q5VXI9	792
SP9	LRP5	O75197	582
SP9	PCSK5	Q92824	547
SP9	TMEM176B	Q3YBM2	542
SP9	DNAAF10	Q96MX6	525
SP9	DLX2	Q07687	503
SP9	GSX2	Q9BZM3	474
SP9	TSHZ1	Q6ZSZ6	437
SP9	DLX1	P56177	436
SP9	ETAA1	Q9NY74	423
SP9	GSX1	Q9H4S2	409
SP9	ASCL1	P50553	404
SP9	STAT3	P40763	402
SP9	VRTN	Q9H8Y1	384

IntAct

4 interactions, top by confidence:

A	B	Type	Score
P		psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
SP7	IGF2BP3	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (14): SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS), SP9 (Proximity Label-MS)

ESM2 similar proteins: A0JC51, A5ABV9, B0X9H6, G5EGB2, O09100, O57311, O60481, O73689, O95409, P07247, P0CG40, P10070, P23769, P23824, P39768, P43694, P46152, P46684, P91623, Q00939, Q08369, Q0Q0E4, Q0VA40, Q0VGT2, Q15915, Q1A1A4, Q4V5A3, Q60987, Q61602, Q62520, Q62521, Q64HY3, Q6DJQ6, Q6P0J3, Q7TQ40, Q8JJC0, Q8N9L1, Q91660, Q91689, Q924Y4

Diamond homologs: A5ABV9, O08876, O14901, O70494, O89090, O89091, P08047, P0CG40, P41696, Q01714, Q02446, Q02447, Q0VA40, Q13351, Q22678, Q3SY56, Q5XGT8, Q62445, Q64HY3, Q64HY5, Q6BEB4, Q6NW96, Q6P0J3, Q8BMJ8, Q8IXZ3, Q8K1S5, Q8TDD2, Q8VI67, Q90WR8, Q9ESX2, Q9JHX2, Q9TZ64, A1C6L9, A1DH89, A2QCJ9, B0XSK6, B8NGC8, G4N3L5, K9GKQ6, O14335

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	2
Uncertain significance	49
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
1297467	NM_001145250.2(SP9):c.1133A>G (p.Glu378Gly)	Pathogenic
1297468	NM_001145250.2(SP9):c.1216del (p.His406fs)	Pathogenic
1297469	NM_001145250.2(SP9):c.1192_1207dup (p.Arg403fs)	Pathogenic
4813568	NM_001145250.2(SP9):c.245C>A (p.Ser82Ter)	Pathogenic
1297466	NM_001145250.2(SP9):c.1133A>C (p.Glu378Ala)	Likely pathogenic
4820605	NM_001145250.2(SP9):c.1230_1231del (p.His410_Ile411insTer)	Likely pathogenic

SpliceAI

168 predictions. Top by Δscore:

Variant	Effect	Δscore
2:174335110:CGGGG:C	donor_loss	1.0000
2:174335111:GGG:G	donor_gain	1.0000
2:174335112:GG:G	donor_gain	1.0000
2:174335112:GGG:G	donor_gain	1.0000
2:174335113:GG:G	donor_gain	1.0000
2:174335114:G:GA	donor_loss	1.0000
2:174335114:G:GG	donor_gain	1.0000
2:174335115:T:G	donor_loss	1.0000
2:174335109:TCGGG:T	donor_gain	0.9900
2:174335110:CGGG:C	donor_gain	0.9900
2:174335111:GGGG:G	donor_gain	0.9900
2:174336103:CTAG:C	acceptor_loss	0.9800
2:174336104:TAGG:T	acceptor_loss	0.9800
2:174336105:AGG:A	acceptor_loss	0.9800
2:174336106:GGAA:G	acceptor_gain	0.9800
2:174336100:A:AG	acceptor_gain	0.9700
2:174336105:A:AG	acceptor_gain	0.9700
2:174336106:G:GG	acceptor_gain	0.9700
2:174336105:AG:A	acceptor_gain	0.9600
2:174336106:GG:G	acceptor_gain	0.9600
2:174336106:GGA:G	acceptor_gain	0.9600
2:174336092:T:G	acceptor_gain	0.9400
2:174336091:A:AG	acceptor_gain	0.9300
2:174336097:C:G	acceptor_gain	0.9300
2:174336101:C:G	acceptor_gain	0.9300
2:174336096:A:AG	acceptor_gain	0.9100
2:174335917:A:AG	donor_gain	0.8200
2:174336104:TAGGA:T	acceptor_gain	0.8200
2:174336105:AGGAA:A	acceptor_gain	0.8200
2:174336106:GGAAG:G	acceptor_gain	0.8200

AlphaMissense

3104 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:174337100:T:A	C339S	1.000
2:174337100:T:C	C339R	1.000
2:174337101:G:A	C339Y	1.000
2:174337101:G:C	C339S	1.000
2:174337131:T:C	L349P	1.000
2:174337139:C:A	H352N	1.000
2:174337139:C:G	H352D	1.000
2:174337140:A:G	H352R	1.000
2:174337141:C:A	H352Q	1.000
2:174337141:C:G	H352Q	1.000
2:174337143:T:C	L353P	1.000
2:174337145:C:A	R354S	1.000
2:174337151:C:G	H356D	1.000
2:174337153:C:A	H356Q	1.000
2:174337153:C:G	H356Q	1.000
2:174337169:T:C	F362L	1.000
2:174337171:C:A	F362L	1.000
2:174337171:C:G	F362L	1.000
2:174337175:T:A	C364S	1.000
2:174337175:T:C	C364R	1.000
2:174337176:G:A	C364Y	1.000
2:174337176:G:C	C364S	1.000
2:174337177:C:G	C364W	1.000
2:174337190:T:A	C369S	1.000
2:174337190:T:C	C369R	1.000
2:174337191:G:A	C369Y	1.000
2:174337191:G:C	C369S	1.000
2:174337192:C:G	C369W	1.000
2:174337198:G:C	K371N	1.000
2:174337198:G:T	K371N	1.000

dbSNP variants (sampled 300 via entrez): RS1000267959 (2:174333694 T>C), RS1000297496 (2:174337594 G>A,T), RS1001373621 (2:174336790 G>A,C,T), RS1001770619 (2:174333314 C>A,T), RS1001824534 (2:174336356 C>T), RS1002902110 (2:174337899 A>G), RS1003088011 (2:174334895 C>T), RS1003369310 (2:174333925 G>A,C), RS1003443712 (2:174335193 C>T), RS1003827712 (2:174334834 C>A), RS1004390868 (2:174334605 C>T), RS1005897712 (2:174338752 A>G), RS1006073213 (2:174333219 C>G), RS1007353292 (2:174338960 A>C), RS1007363610 (2:174338378 TATC>T)

Disease associations

OMIM: gene MIM:621003 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal dominant
complex neurodevelopmental disorder	Moderate	Autosomal dominant

Mondo (3): intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation	1
ferrous chloride	decreases expression	1
abrine	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
Air Pollutants	affects methylation, increases abundance	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Nitrogen Dioxide	affects methylation, increases abundance	1
Aflatoxin B1	decreases methylation	1
Particulate Matter	affects methylation, increases abundance	1

Clinical trials (associated diseases)

392 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays